UK Govt Has ‘Made A Hash’ Of Managing Brexit For Life Sciences Sector
Executive Summary
A recent debate in the House of Lords saw some fiery words exchanged over the government’s plans for the life science sector in the event of a no-deal Brexit, with accusations that they would produce a “clunky” regulatory system and put industry’s future “at grave risk.”
You may also be interested in...
Pharma Uncertainty Remains As UK Votes To Delay Brexit
UK members of parliament have ruled out a no-deal Brexit and voted to request a delay to the exit date, and they will vote again on the withdrawal deal next week. But all this just serves to exacerbate the uncertainty and frustration felt by businesses working in the pharmaceutical sector.
BIA ‘Reassured’ On Post-Brexit SPC Regime But Data Exclusivity Concerns Remain
The government has said it is prepared to discuss the terms of supplementary protection certificates under a UK-only regime if there is a no-deal Brexit, but concerns also linger over the start dates for regulatory data protection.
'Rule Out No-Deal Brexit,' BIA Tells Government
The BioIndustry Association wants the government to rule out a “no-deal” Brexit, saying it would be bad for patients and the life sciences sector.